Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma
This study is a open-lable, , single center, phase II clinical study. Target population is patients with locally resectable osteosarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with adriamycin, cisplatin, ifosfamide and methotrexate in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Osteosarcoma
DRUG: Camrelizumab in Combination With Neoadjuvant Chemotherapy
tumor cell necrosis rate (TCNR), 24 months
2 years Overall Survival (OS) rate, The percentage of patients overall survival in 2 years, 24 months|2 years Progression-free survival (PFS) rate, The percentage of patients Progression-free survival in 2 years, 24 months|Adverse Events (AEs), All adverse event/Serious adverse event that occurred during the study period according to CTCAE, 24 months
In this study, eligible subject will be enrolled into study arm to accept study treatment. Treatment cycles of chemotherapy will be at most 9 cycles which will be decided by investigators. The percentage of the patient with tumor cell necrosis rate \>90% determined by the Independent Review Committee (IRC) will be the primary outcome measures.